Phase 3Completed
A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)
A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate the Efficacy and Safety of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia at Risk for Coronary Heart Disease
- Sponsor
- Organon and Co (Industry)
- Enrollment
- 440 enrolled
- Conditions
- Hypercholesterolemia
- Interventions
- Comparator: rosuvastatin 5 mg + ezetimibe 10 mg; Comparator: rosuvastatin 10 mg; Comparator: rosuvastatin 10 mg + ezetimibe 10 mg; Comparator: rosuvastatin 20 mg
- Ages
- adults, older adults
- Registry
- NCT00783263
Full record on ClinicalTrials.gov
From the registry
A study to evaluate the low-density lipoprotein cholesterol (LDL-C) lowering efficacy of the addition of ezetimibe to rosuvastatin compared with doubling dose of rosuvastatin in participants treated with rosuvastatin alone and not at their National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) LDL-C goal
Primary outcomes
- Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment
History
Last registry update
Results first posted
Primary completion
Started
Registered